← All stocks

Lyell Immunopharma, Inc.

LYEL Net selling
CIK 0001806952 #3374 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$193.37K
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$193.37K
4 of 4 sales
Net
−$193.37K
−$193.37K against sales at will

By person

14 insiders · 4 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Seely Lynn
President and CEO
$149.01K (1)
−$149.01K
63,899
$811.52K
Lee Gary K.
Chief Scientific Officer
$22.64K (1)
−$22.64K
16,220
$205.99K
Hill Stephen J.
Chief Operating Officer
$15.37K (1)
−$15.37K
16,816
$213.56K
Shook David
Chief Medical Officer
$6.35K (1)
−$6.35K
20,423
$259.37K
+1,942%
Innovative Cellular Therapeutics Holdings Ltd entity
10% owner
2,818,980
$35.80M
−7.4%
ARCH Venture Partners IX, LLC entity
10% owner
1,426,528
$18.12M
+52.0%
ARCH Venture Fund XIII, L.P. entity
10% owner
1,426,528
$18.12M
+52.0%
Klausner Richard
Director
843,365
$10.71M
+23.1%
Newton Charles W.
Chief Financial Officer
215,306
$2.73M
Ramachandra Sumant
Director
200,000
$2.54M
Lang Matthew
Chief Business Officer
162,500
$2.06M
+225.0%
BRAWLEY OTIS W
Director
35,640
$452.63K
Aguirre Jarrad Mattieu
Chief Medical Officer
20,279
$257.54K
0.0%
Bulis Veronica Sanchez
VP, Corporate Controller
14,799
$187.95K
+56.6%

No percentages here. This company's share count has moved by a factor of 15.4 over the window, from 19,211,202 to 295,228,868 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Shook David
10 Sep 2026
Chief Medical Officer
Sell
500
$12.70
$6.35K
Lee Gary K.
21 Aug 2026
Chief Scientific Officer
Sell
1,457
$15.54
$22.64K
Hill Stephen J.
21 Aug 2026
Chief Operating Officer
Sell
989
$15.54
$15.37K
Seely Lynn
21 Aug 2026
President and CEO
Sell
9,589
$15.54
$149.01K

What was left out

Form 4 filings counted 5
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 4
Transactions with no price 0
Shares from compensation/vesting 0
History held since 23 Jun 2021